Clinical Trial Update: The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 [Phase 2]

View source ↗

Summary

This is an update on the Phase 2 trial of REC-994 for symptomatic cerebral cavernous malformation. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Cavernous Malformation

Drugs mentioned

• REC-994

Snippet

Sponsor: Recursion Pharmaceuticals Inc. | Conditions: Cerebral Cavernous Malformation | Phase 2 | Status: COMPLETED